Atara Bio to collaborate with Merck on ATA129-Keytruda combo in NPC; shares up 11% premarket

|About: Atara Biotherapeutics (ATRA)|By:, SA News Editor

Thinly traded micro cap Atara Biotherapeutics (NASDAQ:ATRA) is up 11% premarket, albeit on only 559 shares, in response to its announcement of a clinical trial collaboration with Merck evaluating the combination of its allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (ATA129) and Keytruda (pembrolizumab) in patients with platinum-resistant or recurrent EBV-associated nasopharyngeal carcinoma (NPC).

An Atara-sponsored Phase 1/2 study should be initiated next year. Financial terms are not disclosed.

Subscribe for full text news in your inbox